About
Wuxi Xdc Cayman Inc (HK:2268) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 6 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Mar 23 2026
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
Feb 27 2026
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
Feb 27 2026
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
Dec 23 2025
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Financials
Revenue
HK$5.94 B
Market Cap
HK$76.93 B
P/E Ratio
48.15
EPS
1.02